Theriva Biologics Inc's Customers Performance

Name: Theriva Biologics Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

TOVX

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


TOVX's Source of Revenues		• List of TOVX Customers

for the same period Theriva Biologics Inc

• List of TOVX Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Theriva Biologics Inc's Comment on Sales, Marketing and Customers

News about Theriva Biologics inc Contracts

Emerging Synergies VCN-01 and Chemotherapy in the Fight Against Metastatic Pancreatic Cancer

In a landscape where therapeutic advancements for metastatic pancreatic cancer remain critically needed, Theriva Biologics has made notable strides through its VIRAGE Phase 2b clinical trial. Targeting pancreatic ductal adenocarcinoma (PDAC), the trial investigates the combination of VCN-01, a viral-based therapy, with established chemotherapy regimens, including gemcitabine and nab-paclitaxel. Recent announcements highlight significant milestones in the trial s progress and suggest a promising outlook for combining novel and traditional cancer therapies. Enrollment Achievements and Study Design Theriva Biologics successfully achieved its target enrollment of 92 evaluable patients 46 in each of the control a...

Combining Forces: VCN-01 and Liposomal Irinotecan Unleash Synergistic Power against Pancreatic Cancer

In the realm of cancer research, Theriva Biologics, a prominent biotech company, aims to revolutionize pancreatic cancer treatment. Their lead product candidate, VCN-01, has shown promising preclinical results in combination with liposomal irinotecan. This article aims to interpret recent articles discussing the preclinical data that will be presented by Theriva Biologics at the American Society for Cell and Gene Therapy s 27th Annual Meeting. By analyzing the facts and assessing their impact on the company, we can understand the significance of this research for future pancreatic cancer therapies.1. Preclinical Data Supports the Synergy between VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens:T...

Theriva Biologics' VCN-01 Demonstrates Promising Safety Profile in Phase 2b Trial for Metastatic Pancreatic Ductal Adenocarcinoma

Theriva Biologics Receives Positive Recommendation for VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma TrialTheriva Biologics, a leading biopharmaceutical company, announced today that the Independent Data Monitoring Committee (IDMC) has provided a positive recommendation for the continuation of the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic pancreatic ductal adenocarcinoma. The trial, known as VIRAGE, aims to evaluate the safety and efficacy of this innovative treatment approach.The IDMC s recommendation comes after a thorough review of the trial s interim data. It is a significant milestone for Theriva Biologics as it reaffirms the safety profile of VCN-01 and v...

TOVX's Stock Performance relative to it's Customers

TOVX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Theriva Biologics inc	10.37	0.00	-20.62	16
SUBTOTAL	0.00	0.00	0.00	-

Sources: Theriva Biologics inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Theriva Biologics inc’s corporate clients.
For your research, we’ve provided 9 tables on Theriva Biologics inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.